Extracellular vesicles (EVs) are involved in the pathogenesis of many diseases, including cancer development and neurodegeneration. Although their application in liquid biopsy is promising, there are several challenges in EV research and applications as the EV populations are very heterogeneous and the targets of interest are often in low abundance. Appropriate biomarker choice is also critical in enabling selective isolation of disease-specific EVs. These challenges and limited sensitivity in many conventional protein detection methods have impacted how EVs can be utilized effectively in patient diagnosis and monitoring. This summary provides insight on the application of Simoa® technology in EV research, such as the direct measurement of EVs from patient plasma samples targeting tetraspanins (i.e., CD9, CD63, and CD81) and tumor-derived biomarkers (EpCAM, PD-L1). We will also show that EV-derived biomarkers can be successfully profiled using Simoa. Here, we demonstrate the suitability and potential of the Simoa technology in EV-based biomarker discovery and diagnostic applications.
Share this page